➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Moodys
McKesson
AstraZeneca
Mallinckrodt

Last Updated: July 16, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMIFOSTINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Amifostine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002643 Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed Children's Cancer Group Phase 2 1995-04-01 Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
NCT00002643 Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed National Cancer Institute (NCI) Phase 2 1995-04-01 Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
NCT00003048 Amifostine in Treating Patients With Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 2 1997-05-01 RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Amifostine

Condition Name

Condition Name for Amifostine
Intervention Trials
Drug/Agent Toxicity by Tissue/Organ 19
Head and Neck Cancer 15
Lung Cancer 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Amifostine
Intervention Trials
Head and Neck Neoplasms 17
Lung Neoplasms 12
Radiation Injuries 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Amifostine

Trials by Country

Trials by Country for Amifostine
Location Trials
United States 358
Canada 27
Australia 6
China 4
Puerto Rico 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Amifostine
Location Trials
California 20
Illinois 18
Pennsylvania 16
Ohio 14
Michigan 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Amifostine

Clinical Trial Phase

Clinical Trial Phase for Amifostine
Clinical Trial Phase Trials
Phase 4 4
Phase 3 10
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Amifostine
Clinical Trial Phase Trials
Completed 48
Unknown status 18
Terminated 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Amifostine

Sponsor Name

Sponsor Name for Amifostine
Sponsor Trials
National Cancer Institute (NCI) 32
MedImmune LLC 9
Dana-Farber Cancer Institute 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Amifostine
Sponsor Trials
Other 84
NIH 32
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Boehringer Ingelheim
Merck
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.